Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Modine Manufacturing was a standout, benefiting from secular demand in data center cooling and a well-received spinoff of its auto cooling business. Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains positioned favorably due to its first-mover advantage and workflow integration, despite near-term competitive concerns from Edwards Lifesciences.

Analysis

MOD is the cleaner structural winner here: data-center cooling is a capex cycle, not a one-off earnings beat, so the market may still be underestimating the duration of the replacement cycle as hyperscalers keep pushing rack density higher. The second-order effect is margin mix improvement from higher-spec thermal systems, which tends to offset cyclicality in legacy industrial exposure and can re-rate the multiple if investors start treating it like an infrastructure-enablement story rather than a manufacturing story.

ADEA’s strength looks more durable than a simple licensing bounce because IP monetization usually has operating leverage with very little incremental cost, which can create a step-function in FCF if deal flow stays active. The market may be missing the compounding effect: once licensing momentum improves, counterparties often accelerate settlements to avoid litigation uncertainty, which can extend the cycle for several quarters and make reported results look less lumpy than the underlying economics.

ATRC is the more interesting setup on the downside-vs-upside asymmetry. Near-term competitive noise can pressure sentiment, but deep workflow integration in medtech creates switching friction that is typically harder to dislodge than investors expect; the real risk is not share loss overnight but a longer sales-cycle elongation that compresses 2026 growth expectations. EW is the implied pressure valve: if it is winning attention in the category, the bigger read-through may be pricing power and reimbursement discipline, not just product competition. The contrarian view is that ATRC’s moat is likely overstated in a hot narrative market, but underappreciated in installed-base terms—meaning the stock can stay rangebound even if fundamentals remain intact.

Key Decisions for Investors

• Long MOD on pullbacks over the next 1-2 weeks; use the market’s tendency to fade industrial strength after good prints as entry. Risk/reward skews positive into the next 2-3 quarters if data-center demand remains the dominant mix driver.
• Initiate a medium-term long ADEA position, ideally on any post-earnings consolidation. Pair with a smaller short in a lower-quality IP monetization name if available; target is FCF compounding over 6-12 months, with downside limited unless licensing activity normalizes sharply.
• Avoid chasing ATRC strength here; if long, reduce size and treat as a 3-6 month hold only. Best expression is a call spread rather than common stock to cap drawdown if competitive headlines accelerate.
• For a relative-value expression, consider long ADEA / short EW over 2-4 months if you want to express IP monetization versus competitive-medtech scrutiny. The thesis is that ADEA’s earnings leverage is more durable, while EW’s benefit is more incremental and already better understood.
• If ATRC rallies on weak volume, sell into strength rather than add. The setup looks like a sentiment trade, not a clean fundamental re-acceleration, so the better risk/reward is to wait for a better entry or use options.